Virax Biolabs’ proprietary in-development diagnostic technology for post-acute infection syndromes (“PAIS”), such as Long COVID, positions the Company for an important data year ahead, following a series of recent clinical and operational milestones over the past 12 months.
“What if we could finally put real answers behind the brain fog, fatigue, and lingering symptoms so many patients still face post-COVID? In this episode, Dr. Nigel McCracken, Chief Operating Officer at Virax Biolabs, returns to Med Tech Gurus to reveal how their groundbreaking ViraxImmune platform is decoding the hidden dysfunctions of the immune system. With […]
LONDON, Aug. 26, 2025 /PRNewswire/ — Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax” or the “Company”), an innovative biotechnology company focused on immune response detection and diagnostics, today announced it has signed a Research Services Agreement (“RSA”) with Emory University’s Center for the Advancement of Diagnostics for a Just Society (“ADJUST Center”) to conduct clinical studies of ViraxImmune™. […]
Myalgic encephalomyelitis (ME/CFS), also known as chronic fatigue syndrome, is a complex condition characterized by post-exertional fatigue and a range of neuroimmune symptoms. It is one of several debilitating conditions that fall under the diagnostic umbrella of post-acute infection syndrome (PAIS) due to its association with an incomplete recovery from viral disease. ME/CFS often […]
Virax Biolabs are excited to announce our attendance at the 7th European Congress of Immunology (ECI), taking place in Dublin. The Congress runs from 1-4th September, and you can visit our research team at Booth C13. Hosted by the Irish Society for Immunology (ISI) and the European Federation of Immunological Societies (EFIS), this prestigious event […]
